Wedelia trilobata (Sphagneticola trilobata): Benefits, Dosage, Safety & Evidence

Questions fréquentes

How does Wedelia trilobata work to reduce inflammation?

Wedelia trilobata contains active compounds including wedelolactone, luteolin, and kaempferol that demonstrate anti-inflammatory activity through multiple pathways. Wedelolactone inhibits NF-κB signaling and lipoxygenase enzymes, while flavonoids like luteolin reduce pro-inflammatory cytokine production. These compounds work synergistically to modulate inflammatory responses. The sesquiterpene lactones present may also contribute to antipyretic effects by acting on prostaglandin synthesis pathways. Evidence level: C (preclinical studies support these mechanisms, though human clinical trials are limited).

Does Wedelia trilobata interact with any medications?

Limited research exists on specific drug interactions for Wedelia trilobata. Due to its anti-inflammatory properties, it may theoretically potentiate effects of anticoagulant or antiplatelet medications. Wedelolactone affects certain liver enzymes, suggesting potential for herb-drug interactions with medications metabolized by the cytochrome P450 system. Patients taking blood thinners, NSAIDs, or medications with narrow therapeutic indices should consult a healthcare provider before use. Evidence level: C. More clinical research is needed to establish specific interactions.

What is the recommended dosage of Wedelia trilobata?

Traditional preparations use 5-10 grams of dried leaf material prepared as a decoction for internal use. For external applications, fresh leaves are crushed into a paste and applied directly to affected skin areas. Standardized commercial preparations are not widely available, so dosing varies based on traditional preparation methods. There are no established clinical dosage guidelines from regulatory authorities. Users should start with lower doses and consult a qualified herbalist. Evidence level: C (based on traditional use).

Is Wedelia trilobata safe during pregnancy?

Wedelia trilobata is considered unsafe during pregnancy. As a member of the Asteraceae family, it contains compounds that may stimulate uterine contractions or affect fetal development. Traditional use data and preclinical studies suggest potential reproductive toxicity. There is insufficient safety data for breastfeeding, so nursing mothers should also avoid this herb. Pregnant and nursing women should not use Wedelia trilobata. Evidence level: C. Women of reproductive age should use reliable contraception if using this herb therapeutically.

What are the traditional uses of Wedelia trilobata?

Wedelia trilobata has been used traditionally in tropical regions for treating fever, skin conditions, and wounds. Folk medicine practitioners apply leaf preparations topically for skin infections, rashes, and wound healing. The herb is also used internally as an antipyretic to reduce fever. In some Caribbean and Southeast Asian cultures, it is employed for inflammatory conditions. These uses are supported by ethnobotanical surveys and some preclinical research, but human clinical trials are lacking. Evidence level: C.

What are the side effects of Wedelia trilobata?

Reported side effects of Wedelia trilobata primarily involve skin sensitization and allergic reactions, particularly with topical application. As an Asteraceae family member, it may cause contact dermatitis in sensitive individuals. Those with known allergies to plants in the daisy family should avoid use. Internal use may cause gastrointestinal upset in some individuals. No serious adverse events have been documented in traditional use literature, but comprehensive safety studies are lacking. Evidence level: C.

Fiche d'information compilée à partir de PubMed

Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.

Compilé à partir de 30 articles PubMed · modèle : gemma4:31b

Résumé

Wedelia trilobata (also known as Sphagneticola trilobata) is an invasive plant used in traditional medicine for its antioxidant and skin-healing properties [PMID:42288525, 41356470].

Contexte

Wedelia trilobata, also known as the Singapore daisy, is a widely distributed invasive agricultural weed and ornamental plant [PMID:31857180, 42288525]. It is noted for its high environmental adaptability to drought, flooding, low light, and heavy metal stress [PMID:34681947, 38928441, 39649394, 37651793].

Usages traditionnels

It is utilized in traditional medicine for various ailments and is popularly used as a strong antioxidant in Vietnamese folk medicine [PMID:42288525, 37131540].

Composés actifs

The plant contains eudesmanolides [PMID:31857180, 37003362], ent-kaurane diterpenoids [PMID:27070557], and a volatile organic compound profile including p-cymene [PMID:39062734]. Other identified constituents include lignans (syringaresinol-4-O-β-D-glucopyranoside, pinoresinol-4-sulfate, pinoresinol-4-O-β-D-glucopyranoside), indolics (1H-indole-3-carboxylic acid, 1H-indole-3-carbaldehyde), and phenolic glycosides [PMID:26946839]. Metabolomic analysis of flowerheads and leaves identified terpenoids, flavonoids, phenolic acids, lipids, and amino acids [PMID:42288525].

Mécanisme d'action

Wedelolide A, a sesquiterpene lactone from the plant, induces apoptosis and ferroptosis in gastric cancer cells by modulating the Keap1/Nrf2/HO-1 pathway and generating reactive oxygen species (ROS) [PMID:41192684]. Certain eudesmanolides inhibit NO production in LPS-induced microglia BV-2 cells [PMID:31857180]. 1H-indole-3-carboxylic acid has demonstrated inhibitory activity against α-glucosidase [PMID:26946839].

Preuves cliniques

Preuve DTumor cell proliferation

Eudesmanolides exhibited significant anti-proliferative activities against HeLa, HepG2, and SGC-7901 tumor cell lines [PMID:31857180]; Wedelolide B and 1α,4β-Dihydroxy-6α-methacryloxy-8β-isobutyryloxyeudesman-9,12-olide showed pronounced cytotoxic effects against AGS cell lines via apoptosis [PMID:37003362].

Preuve DGastric Cancer

Wedelolide A inhibits gastric cancer cell proliferation through apoptosis and ferroptosis via Keap1/Nrf2 modulation [PMID:41192684].

Preuve DDandruff

Included in a synergistic herbal formulation for complementary bioactive and skin-healing properties against Malassezia furfur and Staphylococcus epidermidis [PMID:41356470].

Preuve DNeuroinflammation

Compound 6 (an eudesmanolide) displayed anti-neuroinflammatory effects by inhibiting NO production in LPS-induced microglia BV-2 cells [PMID:31857180].

Synthèse des preuves

The current evidence is limited to in vitro studies, metabolomic profiling, and botanical research. There are no human clinical trials available in the provided data.

Sources PubMed

1.PMID: 31857180 (2020) — Anti-proliferative and anti-neuroinflammatory eudesmanolides from Wedelia (Sphagneticola trilobata (L.) Pruski). · Fitoterapia
2.PMID: 34681947 (2021) — Responses of Sphagneticola trilobata, Sphagneticola calendulacea and Their Hybrid to Drought Stress. · International journal of molecular sciences
3.PMID: 35031940 (2022) — Pathogen resistance in Sphagneticola trilobata (Singapore daisy): molecular associations and differentially expressed genes in response to disease from a widespread fungus. · Genetica
4.PMID: 38928441 (2024) — Adaptation of the Invasive Plant Sphagneticola trilobata to Flooding Stress by Hybridization with Native Relatives. · International journal of molecular sciences
5.PMID: 39062734 (2024) — Divergence of Phyllosphere Microbial Community Assemblies and Components of Volatile Organic Compounds between the Invasive Sphagneticola trilobata, the Native Sphagneticola calendulacea and Their Hybrids, and Its Implications for Invasiveness.

Wedelia trilobata

Sources et citations

Calculer une dose sûre de Wedelia trilobata